Staar Ramping Up Staarvisc Production Following FDA Approval
This article was originally published in The Gray Sheet
Executive Summary
Staar Surgical's U.S. launch of Staarvisc viscoelastic solution will follow production ramp-up occurring over the next few months, the firm said following receipt of FDA approval July 7.
You may also be interested in...
Anika/Staar Staarvisc II
Sodium hyaluronate viscoelastic device gains FDA approval for use as an ophthalmic surgical aid via premarket approval application, announced April 27. The clear, viscous, injectable substance is used to protect delicate tissues inside the eye during ophthalmic surgeries like cataract removal and intraocular lens implantation. Staar Surgical has licensed the right to sell Staarvisc II from manufacturer Anika Therapeutics, and will offer it as part of a complete package for physicians to use for cataract procedures. Staar's original Staarvisc was approved by FDA in July 1999 (1"The Gray Sheet" July 12, 1999, p. 10)
Anika/Staar Staarvisc II
Sodium hyaluronate viscoelastic device gains FDA approval for use as an ophthalmic surgical aid via premarket approval application, announced April 27. The clear, viscous, injectable substance is used to protect delicate tissues inside the eye during ophthalmic surgeries like cataract removal and intraocular lens implantation. Staar Surgical has licensed the right to sell Staarvisc II from manufacturer Anika Therapeutics, and will offer it as part of a complete package for physicians to use for cataract procedures. Staar's original Staarvisc was approved by FDA in July 1999 (1"The Gray Sheet" July 12, 1999, p. 10)
Staar Surgical
Ophthalmic products company is evaluating a cash offer to acquire 51-100% of its outstanding common stock at $15 per share from an unnamed entity "whose principals have not been disclosed," the firm reports in a June 28 release. Monrovia, California-based Staar makes minimally invasive devices for refractive, cataract and glaucoma surgery including foldable intraocular lenses